Advertisement

Induced Enhanced Resistance to Transplantable Tumors in Mice

  • Paul H. Saluk

Abstract

The first systematic studies of bacterial vaccines in the treatment of human cancer were performed by W. B. Coley (1891, 1893, 1898, 1906). Additional reports of cancer treatment with such vaccines appeared although not all were of a positive nature (reviewed by Nauts et al., 1946). The use of Coley’s toxins (mixtures of Streptococcus pyogenes and Serratia marcescens) fell into disfavor because of a lack of consistency, which was due, in part, to a lack of potency and a lack of knowledge regarding dosage, site of administration, and frequency of injections. However, a case study by Nauts et al. (1953) revealed the effectiveness of Coley’s toxins when these parameters were taken into consideration. Interest in bacterial products was revived by the experiments of Shwartzman and Michailovsky (1932) and of Duran-Reynals (1935) wherein they showed that bacterial filtrates of gram-negative organisms were effective in producing hemorrhagic necrosis of murine tumors.

Keywords

Serratia Marcescens Antitumor Response Peritoneal Cell Transplantable Tumor Ascites Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, P., and Evans, R., 1971, Endotoxin and double stranded RNA render macrophages cytotoxic, Nature New Biol. 232:76.PubMedGoogle Scholar
  2. Andervont, H. B., 1936, The reaction of mice and of various mouse tumors to the injection of bacterial products, Am. J. Cancer 27:77.Google Scholar
  3. Berendt, M. J., and Saluk, P. H., 1976, Tumor inhibition in mice by lipopolysaccharide-induced peritoneal cells and an induced soluble factor, Inject. Immun. 14:965.Google Scholar
  4. Berendt, M. J., Mezrow, G. F., and Saluk, P. H., 1978a, Requirement for a radiosensitive lymphoid cell in the generation of lipopolysaccharide-induced rejection of a murine tumor allograft, Infect. Immun. 21:1033.PubMedGoogle Scholar
  5. Berendt, M. J., North, R. J., and Kirstein, D. P., 1978b, Ehe immunological basis of en-dotoxin-induced tumor regression: Requirement for T-cell-mediated immunity, J. Exp. Med. 148:1550.PubMedCrossRefGoogle Scholar
  6. Berendt, M. J., North, R. J., and Kirstein, D. P., 1978c, The immunological basis of en-dotoxin-induced tumor regression: Requirement for a pre-existing state of concomitant anti-tumor immunity,JExp. Med. 148:1560.CrossRefGoogle Scholar
  7. Berendt, M. J., Newborg, M. F., and North, R. J., 1980, Increased toxicity of endotoxin for tumor-bearing mice and mice responding to bacterial pathogens: Macrophage activation as a common denominator, Infect. Immun. 28:645.PubMedGoogle Scholar
  8. Bianco, C., Griffin, E. M., and Silverstein, S. C., 1975, Studies of the macrophage complement receptor: Alteration of receptor function upon macrophage activation, J. Exp. Med. 141:1278.PubMedCrossRefGoogle Scholar
  9. Blarney, R. W., Crosby, D. L., and Baker, J. M., 1969, Reticuloendothelial activity during the growth of rat sarcomas, Cancer Res. 29:335.Google Scholar
  10. Bober, E. A., Kranepool, M. J., and Hollander, V. P., 1976, Inhibitory effect of endotoxin on the growth of plasma cell tumor, Cancer Res. 36:927.PubMedGoogle Scholar
  11. Butler, R. C., Abdclnoor, A., and Nowotny, A., 1978, Bone marrow colony-stimulating factor and tumor resistance-enhancing activity of postendotoxin mouse sera, Proc. Natl. Acad. Sci USA 75:2893.PubMedCrossRefGoogle Scholar
  12. Carswell, E. A., Old, E. J., Kassel, R. E., Green, S., Fiore, N., and Williamson, B., 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. USA 72:3666.PubMedCrossRefGoogle Scholar
  13. Coley, W. B., 1891, Contribution to the knowledge of sarcoma, Ann. Surg. 14:199.PubMedCrossRefGoogle Scholar
  14. Coley, W. B., 1893, Ehe treatment of malignant tumors by repeated inoculations of erysipelas, with a report of original cases, Am. J. Med. Sci. 105:487.CrossRefGoogle Scholar
  15. Coley, W. B., 1898, Ehe treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiosus: Immediate and final results in one hundred and forty cases,J. Am. Med. Assoc. 31:389.CrossRefGoogle Scholar
  16. Coley, W. B., 1906, Eate results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus, Am. J. Med. Sci. 131:376.Google Scholar
  17. Doe, W. F., and Henson, P. M., 1978, Macrophage stimulation by bacterial lipopolysac-charides. I. Cytolytic effect on tumor target cells, J. Exp. Med. 148:544.PubMedCrossRefGoogle Scholar
  18. Duran-Reynals, F., 1935, Reaction of spontaneous mouse carcinomas to blood-carried bacterial toxins, Proc. Soc. Exp. Biol. Med. 32:1517.Google Scholar
  19. Fidler, I. J., Darnell, J. H., and Budman, M. B., 1976, In vitro activation of mouse macrophages by rat lymphocyte mediators,J. Immunol. 117:666.PubMedGoogle Scholar
  20. Grant, C. K., and Alexander, P., 1974, Nonspecific cytotoxicity of spleen cells and the specific cytotoxic action of thymus-derived lymphocytes in vitro, Cell. Immunol. 14:46.PubMedCrossRefGoogle Scholar
  21. Green, S., Dobrjansky, A., Carswell, E., Kassel, R., Old, L., Fiore, N., and Schwartz, M., 1976, Partial purification of a serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. USA 73:381.PubMedCrossRefGoogle Scholar
  22. Grohsman, J., and Nowotny, A., 1972, The immune recognition of TA3 tumors, its facilitation by endotoxin, and abrogation by ascites fluid,J. Immunol. 109:1090.PubMedGoogle Scholar
  23. Hibbs, J. B., Jr., Taintor, R. R., Chapman, H. A., Jr., and Weinberg, J. B., 1977, Macrophage tumor killing: Influence of the local environment, Science 197:279.PubMedCrossRefGoogle Scholar
  24. Hoffman, M., Oettgen, H., Old, L., Mittler, R., and Hämmerling, U., 1978, Induction and immunological properties of tumor necrosis factor, J. Reticuloendothelial Soc. 23:307.Google Scholar
  25. Ikawa, M., Koepfli, J. B., Mudd, S. G., and Niemann, C., 1952, An agent from E. coli causing hemorrhage and regression of an experimental mouse tumor. I. Isolation and properties,J. Natl. Cancer Inst. 13:157.PubMedGoogle Scholar
  26. Kassel, R., Old, L., Carswell, E., Fiore, N., and Hardy, W., 1973, Serum-mediated leukemia cell destruction in AKR mice: Role of complement in the phenomenon, J. Exp. Med. 138:925.PubMedCrossRefGoogle Scholar
  27. Levy, G. A., and Edgington, T. S., 1980, Lymphocyte cooperation is required for amplification of macrophage procoagulant activity, J Exp. Med. 151:1232.PubMedCrossRefGoogle Scholar
  28. Männel, D. N., Rosenstreich, D. L., and Mergenhagen, S. E., 1979, Mechanism of lipo-polysaccharide-induced tumor necrosis: Requirement for lipopolysaccharide-sensitive lymphoreticular cells, Infect. Immun. 24:573.PubMedGoogle Scholar
  29. Männel, D. N., Moore, R. N., and Mergenhagen, S. E., 1980, Macrophages as a source of tumoricidal activity (tumor necrosis factor), Infect. Immun. 30:523.PubMedGoogle Scholar
  30. Mizuno, D., Yoshioka, O., Akamatu, M., and Kataoka, T., 1968, Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide, Cancer Res. 28:1531.PubMedGoogle Scholar
  31. Nauts, H. C., Swift, W. E., and Coley, B. L., 1946, The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M. D., reviewed in the light of modern research, Cancer Res. 6:205.PubMedGoogle Scholar
  32. Nauts, H. C., Fowler, G. A., and Bogatko, F. H., 1953, A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man, Acta Med. Scand. 145(Suppl. 276): 103.Google Scholar
  33. Nelson, D. S., and Kearney, R., 1976, Macrophages and lymphoid tissues in mice with concomitant tumour immunity, Br. J. Cancer 34:221.PubMedCrossRefGoogle Scholar
  34. North, R. J., and Kirstein, D. P., 1977, T-Cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites, J Exp. Med. 145:275.PubMedCrossRefGoogle Scholar
  35. Nowakowski, M., Edelson, P. J., and Bianco, C., 1980, Activation of C3H JHeJ macrophages by endotoxin,J. Immunol. 125:2189.PubMedGoogle Scholar
  36. Nowotny, A., Golub, S., and Key, B., 1971, Fate and effect of endotoxin derivatives in tumor-bearing mice, Proc. Soc. Exp. Biol. Med. 136:66.PubMedGoogle Scholar
  37. Parr, I., Wheeler, E., and Alexander, P., 1973, Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA, Br. J. Cancer 27:370.PubMedCrossRefGoogle Scholar
  38. Roubin, R., Kennard, J., Foley, D., and Zola-Pazner, S., 1981, Markers of macrophage heterogeneity: Altered frequency of macrophage subpopulations after various pathologic stimuli,J. Reticuloendothelial Soc. 29:423.Google Scholar
  39. Ruco, L. P., and Meltzer, M. S., 1978, Macrophage activation for tumor cytotoxicity: Development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions,J. Immunol. 121:2035.PubMedGoogle Scholar
  40. Russell, S. W., Doe, W. F., and Mcintosh, A. T., 1977, Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors,JExp. Med. 146:1511.CrossRefGoogle Scholar
  41. Ryan, J. L., Glode, L. M., and Rosenstreich, D. L., 1979, Lack of responsiveness of C3H JHeJ macrophages to lipopolysaccharide: The cellular basis of LPS-stimulated metabolism,J. Immunol. 122:932.PubMedGoogle Scholar
  42. Saluk, P. H., Edmundowicz, S., Wrigley, D. M., and Tabor, D. R., 1981, Co-expression of enhanced spreading, ingestion, and inhibition of tumor cell proliferation by macrophages from lipopolysaccharide-injected mice, Cancer Immunol. Immunother. 11:159.CrossRefGoogle Scholar
  43. Shear, M. J., 1941, Effects of a concentrate from B. prodigiosus filtrate on subcutaneous primary induced mouse tumors, Cancer Res. 1:731.Google Scholar
  44. Shear, M. J., 1943, Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhagic-producing bacterial polysaccharide, J. Natl. Cancer Inst. 4:461.Google Scholar
  45. Shear, M. J., and Turner, F. C., 1943, Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens Bacillus prodigiosus) culture filtrate, J. Natl. Cancer Inst. 4:81.Google Scholar
  46. Shear, M. J., Perrault, A., and Adams, J. R., 1943, Chemical treatment of tumors. VI. Method employed in determining the potency of hemorrhage-producing bacterial preparations,J. Natl. Cancer Inst. 4:105.Google Scholar
  47. Shwartzman, C., and Michailovsky, N., 1932, Phenomenon of local skin reactivity to bacterial filtrates in the treatment of mouse sarcoma 180, Proc. Soc. Exp. Biol. Med. 29: 737.Google Scholar
  48. Tabor, D. R., and Saluk, P. H., 1981, The functional heterogeneity of murine resident macrophages to a chemotactic stimulus and induction of C3b-receptor-mediated ingestion, Immunol. Lett. 3:371.PubMedCrossRefGoogle Scholar
  49. Tripodi, D., Hollenbeck, L., and Pollack, W., 1970, The effect of endotoxin on the implantation of a mouse sarcoma, Int. Arch. Allergy Appl. Immunol. 37:575.PubMedCrossRefGoogle Scholar
  50. Weinberg, J. B., Chapman, H. A., Jr., and Hibbs, J. B., Jr., 1978, Characterization of the effects of endotoxin on macrophage tumor cell killing,J. Immunol. 121:72.PubMedGoogle Scholar
  51. Wilton, J. M., Rosenstreich, D. L., and Oppenheim, J. J., 1975, Activation of guinea pig macrophages by bacterial lipopolysaccharide requires bone-marrow-derived lymphocytes,J. Immunol. 114:388.PubMedGoogle Scholar
  52. Wrigley, D. M., and Saluk, P. H., 1981, Induction of C3b-mediated phagocytosis in macrophages by distinct populations of lipopolysaccharide-stimulated lymphocytes, Infect. Immun. 34:780.PubMedGoogle Scholar
  53. Yang, C., and Nowotny, A., 1974, Effect of endotoxin on tumor resistance in mice, Infect, Immun. 9:95.Google Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • Paul H. Saluk
    • 1
  1. 1.Department of Microbiology and ImmunologyHahnemann Medical College and HospitalPhiladelphiaUSA

Personalised recommendations